QMENTA's AI tool detects CVS for MS diagnosis

💊🧠 For all our sciences friends out there… did you know? As a marketing agency specialised in pharma and life sciences, we’re always scanning the horizon for the innovations shaping tomorrow’s clinical research. Sharing these stories is how we help keep our network ahead of the curve. One company making waves here is QMENTA,  with an AI-powered neuroimaging platform that: ✔️ Automates CVS detection ✔️ Brings consistency to imaging analysis in trials ✔️ Strengthens evidence generation for new therapies 👉 Definitely one to keep an eye on. 🔗 Check it out: https://hubs.la/Q03Dldz10 #Pharma #MultipleSclerosis #Neuroimaging #AIinHealthcare #ClinicalResearch #MedicalImaging

🧠 The Role of the Central Vein Sign in MS Diagnosis The Central Vein Sign (CVS) is emerging as an important imaging biomarker that may strengthen the McDonald criteria for Multiple Sclerosis. Its use could support earlier and more reliable diagnosis in both research and clinical settings. 👉 Read the full article: https://hubs.la/Q03DCnNQ0 #MultipleSclerosis #MSResearch #Neuroimaging #MedicalImaging #HealthcareInnovation

TBI research is moving into a new chapter. We’ve known for a long time that brain injury can set the stage for neurodegeneration, but actually tracking those molecular changes in patients has been a challenge. Part of the difficulty comes from the wide range of injury parameters (severity, frequency, mechanism) and the even wider range of sequelae that follow. No two TBIs look alike and that complexity has slowed progress in predicting outcomes and tailoring treatments. A recent review in Frontiers in Neurology (Giarratana AO, 2025) stood out to me because it shows how PET biomarkers can help bring order to that complexity: ✅ Amyloid and tau imaging tie TBI pathology to Alzheimer’s-like processes 🧠 Neuroinflammation tracers pick up on persistent microglial activation long after the injury 🔬 Metabolic and neurotransmitter PET shine a light on disrupted circuitry What I really like is the use of the term neurotheranostic — tools that don’t just describe pathology, but guide interventions. My research in TBI and neuroinflammation keeps pointing to the same truth: we need tools that bridge mechanism to medicine. Neurotheranostics feels like a step in that direction. The aim should be to benefit every patient from "mild" injuries to the most severe cases. 👉 Here’s the link if you want to take a look: https://lnkd.in/d4ygvvfM #Neuroscience #TraumaticBrainInjury #Neurotheranostics #Neurodegeneration #PETImaging #PrecisionMedicine #TranslationalResearch

🧠 This week in the European Radiology Journals Newsletter 📰✨ From stroke prediction to neurodegenerative disease imaging, explore the latest research in brain health and beyond: ✅ Predicting hematoma expansion in hypertensive ICH ✅ Radiomics & hematoma risk prediction 🤖 ✅ Skull-brain decoupling & head impacts 🏈 ✅ Subarachnoid hemorrhage classification on CT ✅ MR & PET in neurodegenerative disease 🧬 🔗 Read the full newsletter here: https://buff.ly/5PjPaMN

Our new course, Effective Communication Techniques for Imaging Patients with Neurodegenerative Disorders, provides an overview of effective communication techniques for imaging patients with neurodegenerative disorders, highlighting the importance of communication support, as well as the role of medical imaging in diagnosis and treatment. Start Learning today: https://zurl.co/SfecC #RadiologyEducation #MedicalImaging #Radiographers #ContinuingEducation #ARRT #ASRTApproved #CQR #StructuredEducation #PatientCare #Neuroimaging

Neuronal brain tumors are an uncommon group of central nervous system tumors that arise from cells with neuronal differentiation. These tumors may be purely neuronal in origin or have mixed neuronal and glial components, which comprise a subset of glioneuronal tumors. Submit related content for Journal of Neurological Sciences and Research Read latest published article: https://lnkd.in/dZc8QK7Q #neurologicalresearch #glioneuronaltumor #researchers #openaccess #submitnow

Since I created the original slide in May 2025, there have been numerous updates to the treatment landscape in generalized Myasthenia Gravis. This is the latest edition of the slide. Most notable and immediate is the pending FDA review in December 2025 for Inebilizumab-CDON. Potential ORAL options are emerging in the complement inhibitor space, the B cell modulator space and the T cell depletion strategies. Most interesting is what is happening on the far left of the diagram, with NMD and COUR pharma's emerging candidates. We could not help advance the science without the help of our fine collaborators Muscular Dystrophy Association and #MyastheniaGravisFoundationMichigan and their president and relentless rare disease advocate Susan Woolner, CPXP. #Neuromuscular #Neurology Muscular Dystrophy Association Michigan State University

Most people think pain starts where it hurts. But in reality, pain is processed — and often amplified — in the brain. In sickle cell disease, we’re seeing: - Altered brain connectivity in pain-processing networks - Cerebral blood flow changes even outside of pain crises - Links between brain activity and cognitive performance These findings could open doors to brain-targeted treatments that complement traditional care. 💬 If brain imaging could guide your treatment plan, what would you want it to reveal? #Neuroimaging #SickleCell #PainResearch #BrainHealth

Early signs of hope for Parkinson’s treatment For over 200 years, Parkinson’s disease has had no cure. Medicines can ease symptoms, but they can’t replace the brain cells that are lost. Now, scientists in Japan, the U.S., and Sweden are trying something new: transplanting lab-grown brain cells that make dopamine directly into patients’ brains. Early results look promising. The new cells are surviving, connecting with the brain, and producing dopamine. Brain scans show higher dopamine levels, and patients who received larger doses are already moving better. In Europe, only eight people have joined a trial called STEM-PD. One of them, Andy, said the surgery was scary but worth the risk: “If this helps—even a little—it will have been worth it.” Doctors say it could take years for the new cells to fully work, but the first signs give real hope. The U.S. FDA has already cleared a Phase 3 trial, the final step before possible approval. Around the world, scientists are now racing—together and in competition—to bring the first stem cell therapy for Parkinson’s to patients. For the millions still waiting, this could finally change everything. #ParkinsonsDisease #StemCellTherapy #MedicalBreakthrough #Neuroscience #ParkinsonsResearch #RegenerativeMedicine #FutureOfMedicine #BrainHealth #NeurodegenerativeDiseases #MedicalInnovation #StemCellsInMedicine #HealthcareAdvancements #NeuroScienceResearch #Biotechnology #CellTherapy #FDAApproval #ClinicalTrials #HopeForParkinsons #MedicalFrontiers #NeuroRegeneration #ScienceAndHope #DopamineCells #NeuroInnovation #CuttingEdgeMedicine #FutureHealthcare #ResearchInMedicine #ParkinsonsAwareness #BrainCellTherapy #ScienceUpdates #NextGenMedicine #MedicalProgress #ExperimentalTherapies #InnovationsInHealthcare #HopeInScience #TranslationalMedicine #StemCellResearch #BreakthroughInScience #HealthcareRevolution #FutureCures #PatientStories #NeuroRestoration #ScientificAdvances #FutureOfHealthcare #MedicineAndTechnology #GlobalResearch #ScienceChangingLives #ParkinsonsHope #BrainTherapy #HealingWithScience #HopeForMillions

Our highly cited paper “Glymphatic System Pathology and Neuroinflammation as Two Risk Factors of Neurodegeneration” has just been highlighted in the Cells journal “Cells of the Nervous System” Section. This article explores how dysfunctions of the glymphatic system and neuroinflammation contribute to the progression of neurodegenerative diseases — a topic that is attracting increasing scientific attention worldwide. 🧠 Why is this important? Because understanding these mechanisms opens the door to novel therapeutic and neuromodulation strategies. In this context, it also links directly to our ongoing work with transcranial stimulation technologies such as photobiomodulation, transcranial direct current stimulation or transcranial pulse stimulation, which aim to support brain health and resilience. 👉 I warmly invite you to read the full article here: 🔗 https://brnw.ch/21wVcoo Let’s keep pushing the boundaries of neuroscience and neurotechnology! Global Brain Care CAS in Brain Health Longevity Center | Europe Magwise Medical Centre Minds Of Hope | Instytut BezStresu Neuronic QVITI S.A.